Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities (July 2021) - Immune Responses

Ontario Institute for Cancer Research (Toronto, Ontario)

$499,025.00

Correlates of COVID-19 vaccine-induced protection and host factors that affect immune response

EF 2021-22

Résumé
Background: Canada is seeing a COVID-19 resurgence as SARS-CoV-2 variants continue to emerge globally and herd immunity remains elusive. It is unclear whether there will be a decline in immune protection over time, or with the emergence of viral variants. Methods: From December 2020 to June 2021, invitations went out to select Ontario Health Study participants requesting that they complete an online questionnaire and submit dried blood spot samples. The questionnaire includes details around vaccination, previous COVID-19 infection, and underlying medical conditions and medications taken. The study included 10,569 participants (age 21 to 93), with 62% women. Collection of second dried blood spot samples is underway. Dried blood spot samples will be tested for antibodies to SARS-CoV-2 (anti-spike IgG, anti-receptor binding domain of spike (RBD) IgG, and anti-nucleocapsid (N) IgG) and will undergo DNA extraction and genotyping. Data will be linked to COVID-19 lab results and hospitalization data, including ICU admission and death. Objectives: Measured levels of vaccine-induced immune markers (antibody levels) will be related to vaccine effectiveness by comparing incidence of SARS-CoV-2 infection, hospitalization, and mortality in a population of vaccinated and unvaccinated participants. We will also assess variation in immune response to vaccination by viral variant, vaccine factors (such as type, product, number of doses, interval between doses, time since vaccination) and intrinsic host factors (such as age, sex, genetics, and comorbidities). Implications: Identifying immune correlates of protection will be important because they can be used as surrogate endpoints in assessing vaccine efficacy, and the durability of protection over time will provide insights into the necessity for booster vaccination. Also, identification of host and vaccine factors that affect immunity will allow for tailored recommendations regarding vaccine distribution.
Programme
Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities (July 2021) - Immune Responses
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
459285
Name
Kirsh Victoria
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: Emerging COVID-19 Research Gaps & Priorities (July 2021)
Projecttitle
Correlates of COVID-19 vaccine-induced protection and host factors that affect immune response
Programtype2
Operating Grants
Orgnameinp2
Ontario Institute for Cancer Research (Toronto, Ontario)
Cihramount2
$499,025
Cihrequipment2
$0
Programname2
Op. Gr.:Emerging COVID-19 Res. Gaps & Priorities (July 2021) - Immune Responses
Keyworddelim
Cell-Mediated Immunity; Correlates Of Protection; Covid-19 Vaccination; Humoral Immunity; Immune Response; Vaccine Brand
Abstract
Background: Canada is seeing a COVID-19 resurgence as SARS-CoV-2 variants continue to emerge globally and herd immunity remains elusive. It is unclear whether there will be a decline in immune protection over time, or with the emergence of viral variants. Methods: From December 2020 to June 2021, invitations went out to select Ontario Health Study participants requesting that they complete an online questionnaire and submit dried blood spot samples. The questionnaire includes details around vaccination, previous COVID-19 infection, and underlying medical conditions and medications taken. The study included 10,569 participants (age 21 to 93), with 62% women. Collection of second dried blood spot samples is underway. Dried blood spot samples will be tested for antibodies to SARS-CoV-2 (anti-spike IgG, anti-receptor binding domain of spike (RBD) IgG, and anti-nucleocapsid (N) IgG) and will undergo DNA extraction and genotyping. Data will be linked to COVID-19 lab results and hospitalization data, including ICU admission and death. Objectives: Measured levels of vaccine-induced immune markers (antibody levels) will be related to vaccine effectiveness by comparing incidence of SARS-CoV-2 infection, hospitalization, and mortality in a population of vaccinated and unvaccinated participants. We will also assess variation in immune response to vaccination by viral variant, vaccine factors (such as type, product, number of doses, interval between doses, time since vaccination) and intrinsic host factors (such as age, sex, genetics, and comorbidities). Implications: Identifying immune correlates of protection will be important because they can be used as surrogate endpoints in assessing vaccine efficacy, and the durability of protection over time will provide insights into the necessity for booster vaccination. Also, identification of host and vaccine factors that affect immunity will allow for tailored recommendations regarding vaccine distribution.
Competitiondate
202109
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kirsh, Victoria; Awadalla, Philip
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $499,025~ $0~